InvestorsHub Logo
Replies to #122 on Evolus (EOLS)
icon url

enthalpy

02/07/20 1:18 PM

#123 RE: DewDiligence #122

well I still evolus has a better chance than Revance due to doctor is changing fees for injections. its more appealing repeat business more frequently than once a year.

I just wish this lawsuit would be finished. FDA rejected Allergan. If it's the same arguments should be the same outcome
icon url

enthalpy

02/07/20 1:28 PM

#125 RE: DewDiligence #122

either way GLTU